

# Clinical Application and Use of Rotational Atherectomy System



**Young-Guk Ko, M.D.**

*Severance Cardiovascular Hospital, Yonsei University Health System,  
Seoul, Korea*



# Theoretical Advantage of Atherectomy



Balloon



Problem 1: recoil / restenosis  
Problem 2: dissection

Stents



Problem 1: intimal hyperplasia  
Problem 2: mechanical stress in  
joint orientated  
vessel segments


Atherectomy removes  
the plaque without  
overstretch of the  
vessel wall





# Risk of Stent Fractures



- 1 radial deformation: compression
- 3 axial deformations: extension/contraction, torsion, flexion



# Stent Fracture and Restenosis in SFA






*Scheinert D. et al, JACC 2005*





# Atherectomy Devices



# Benefits of Atherectomy








- Debulking (Plaque burden reduction) & luminal gain
- Removal of calcium and thrombus
- Less dissection, less need for stenting
- Side branch preservation
- Improved drug delivery



# SYSTEM EVOLUTION

Continuous innovation to support your success

JETSTREAM	JETSTREAM G2™	JETSTREAM G2 NXT	JETSTREAM G3™	JETSTREAM G3 GTI	JETSTREAM Navitus™	JETSTREAM Navitus™ L	JETSTREAM™ XC/SC
September 2008	February 2009	August 2009	January 2010	December 2010	March 2011	April 2012	April 2013
<ul style="list-style-type: none"> <li>• First commercially available Pathway Medical product</li> <li>• Expandable blades</li> <li>• Aspiration port integrated into distal cutter</li> <li>• 8 F introducer sheath</li> </ul>  <p>Distal Cutter - 10 Flute Design</p>	<ul style="list-style-type: none"> <li>• Aspiration port moved proximal of cutting blades</li> <li>• Macerator added - 10% increase in aspiration efficiency<sup>1</sup></li> <li>• Approved for thrombectomy</li> </ul>  <p>Macerator Added to Aspiration Port to Decrease Size of Plaque Before it is Aspirated</p>	<ul style="list-style-type: none"> <li>• Pebax outer shaft and stainless steel hypotube (reduced OD, compared to earlier generation designs)</li> <li>• 7 F compatibility</li> <li>• Improved trackability (compared to earlier generation designs)</li> </ul>	<ul style="list-style-type: none"> <li>• 5-flute distal cutter design</li> <li>• Increased torque (power) - 54% increase in differential cutting efficiency<sup>1</sup></li> <li>• 11% increase in aspiration efficiency<sup>2</sup></li> </ul>  <p>Distal Cutter - 5 Flute Design</p>	<ul style="list-style-type: none"> <li>• Increased ease of use/ reliability (compared to JETSTREAM G3)</li> <li>- New liner over driveline</li> <li>- Improved distal bushing</li> <li>- Enhanced GW management</li> <li>- Improved User Interface</li> </ul>	<ul style="list-style-type: none"> <li>• Robust Bushing and Distal Liner (same as GTI)</li> <li>- Elimination of bushing tail related wire sticking</li> <li>- Protection against thrombus stick</li> <li>- Durable liner with improved aspiration.</li> <li>• Guidewire management enhancements for smoother operation over the wire</li> </ul>	<ul style="list-style-type: none"> <li>• Largest JetStream Catheter - 2.4 mm / 3.4 mm - 30% larger lumens<sup>3</sup></li> <li>• Shortened Coupler - Improved performance in torturous anatomy</li> <li>• Navitus technology integrated</li> <li>- Identical liner and bushing technology</li> <li>- Guidewire management enhancements</li> </ul> 	<ul style="list-style-type: none"> <li>• Entire portfolio redesign</li> <li>• New ergonomic POD design - 32% smaller than previous</li> <li>- Redesigned user interface</li> <li>- Improved wire GARD simplifies wire management</li> <li>- New package and POD design reduces environmental footprint</li> </ul> 

1. Compared to JETSTREAM G2 NXT in blades down during bench testing  
 2. Compared to JETSTREAM G2 NXT in bench testing  
 3. Data on file report EV09194

JETSTREAM™ Atherectomy System is manufactured and distributed in EU by Bayer Interventional

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations.

# Pathway PVD Trial



- 172 patients with 210 lesions
- Lesion location:
  - SFA (64%)
  - Popliteal artery (28%)
  - Tibial artery (including TPT) (9%)
- Lesion length: 27.4 ± 23.9 mm
- Stenting: 7%
- Complications:
  - abrupt closures 1%
  - dissections 9%
  - minor embolizations 10%
  - perforations 2%
- **TLR: 26% at 12 months**
- **1-year restenosis rate: 38.2%**







# DCB Global Registries



1406 patients (1773 lesions)  
Lesion length  $12.1 \pm 9.5$  cm

691 patients  
Lesion length  $10.1 \pm 8.4$  cm




LINC 2017

VIVA 2016



# Limitations of Balloon Angioplasty



# Challenges to DCB



- Long lesions:
  - *more plaque burden, higher risk of dissection*
- Calcification:
  - *difficult to dilate, more residual stenosis, higher risk of dissection, insufficient drug delivery*
- ISR lesions:
  - *remaining neointimal burden (residual stenosis)*



# IN.PACT Global Long Lesion Imaging Cohort



Lesions (N)	164
<b>Lesion Type:</b>	
de novo	83.2% (134/161)
restenotic (no ISR)	16.8% (27/161)
ISR	0.0% (0/161)
<b>Lesion Length</b>	<b>26.40 ± 8.61 cm</b>
<b>Total Occlusions</b>	<b>60.4% (99/164)</b>
<b>Calcification</b>	<b>71.8% (117/163)</b>
Severe	19.6% (32/163)
<b>RVD (mm)</b>	<b>4.594 ± 0.819</b>
<b>Diameter Stenosis (pre-treatment)</b>	<b>90.9% ± 14.2</b>
<b>Dissections: 0</b>	<b>37.9% (61/161)</b>
A-C	47.2% (76/161)
D-F	14.9% (24/161)

Procedural Characteristics	
<b>Device Success</b> <sup>[1]</sup>	99.5% (442/444)
<b>Procedure Success</b> <sup>[2]</sup>	99.4% (155/156)
<b>Clinical Success</b> <sup>[3]</sup>	99.4% (155/156)
<b>Pre-dilatation</b>	89.8% (141/157)
<b>Post-dilatation</b>	39.1% (61/156)
<b>Provisional Stent</b>	40.4% (63/156)
LL 15-25 cm:	33.3% (33/99)
LL > 25 cm:	52.6% (30/57)

- 1. Device success:** successful delivery, inflation, deflation and retrieval of the intact study balloon device without burst below the RBP
- 2. Procedure success:** residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by core lab (if core lab was not available then the site reported estimate was used)
- 3. Clinical success:** procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge






# IN.PACT Global Long Lesion Imaging Cohort




## Overall primary patency



Number of subjects at risk*	Baseline (day 0)	6 mo	12 mo
IN.PACT™ DCB	157	142	119

## Primary patency: long vs. very long



Number of subjects at risk	Baseline (day 0)	6 mo	12 mo
Lesion Length 15-25 cm	100	92	81
Lesion Length >25 cm	57	50	38






Claudication, both legs


ESRD on HD

HTN


DM





# Intraluminal Balloon Angioplasty



## Balloon Angioplasty



# After Balloon Angioplasty






# Calcium: Challenge for DCBs




## Calcium Limits Vessel Expansion<sup>1</sup>

Significant difference in vessel compliance leads to overstretch in non-diseased tissue causing dissections, recoil, excessive injury, and poor outcomes



**Figure 12.1. Elastic Recoil After PTCA of Calcified Lesions**  
 Rather than cracking the hard, calcified atheroma, PTCA causes stretching of the contralateral plaque-free wall segment and ineffective dilatation.  
Freed MS, Safian RD; Manual of Interventional Cardiology, Ch. 12, 245-254



*Fanelli J Endovas Ther 2012;19:571-580*


*Fanelli et al. Cardiovasc Intervent Radiol (2014;37:898)*



# DEFINITIVE AR



**Purpose:** Pilot study designed to assess and estimate the effect of treating a vessel with directional atherectomy + DCB (DAART) compared to treatment with DCB alone



Registry arm for severely calcified lesions created to limit bail-out stenting (and therefore variables) in randomized arm.

\* Directional Atherectomy + Anti-Restenotic Therapy



# Technical Success



## Technical Success

Defined as  $\leq 30\%$  residual stenosis following the protocol-defined treatment at the target lesion as determined by the Angiographic Core Laboratory.

	DAART	DCB	P Value
<b>Technical Success</b>	89.6%	64.2%	0.004

## Adjunctive Therapy

(Post protocol-defined treatment)

	DAART (N = 48)	DCB (N = 54)	P Value
<b>Adjunctive Therapy</b>			
PTA (post-)	6.3% (3/48)	33.3% (18/54)	0.0011
Bail-out Stent	0	3.7% (2/54)	0.4968




# DEFINITIVE AR Study



## Key Study Outcome at 12 Months

*DUS Patency - Potential Advantage Emerging in Long and Severely Calcified Lesions*



Lesion length:  
10 ~11 cm

Bail-out stenting:  
DAART 0% vs.  
DCB 3.7%



Thomas Zeller, MD

Per Core Lab Assessment. "All Severe Ca++" group includes all patients treated with DAART therapy including randomized and non-randomized patients with severe calcium.





# Atherectomy & DCB



# Comparison with Other Atherectomy Devices



FEATURE		Jetstream	Orbital	Directional	Laser	BENEFIT
<b>Labeling Indication</b>	Atherectomy	✓	✗	✗	✗	Complex lesions and total occlusion often contain mixed morphology lesions, requiring a device capable of managing it all.
	Thrombectomy	✓				
<b>Active Aspiration</b>		✓				Aspiration of liberated debris may minimize the risk of distal embolization.
<b>Front Cutting / Rotational Device</b>		✓	✗		✗	Total occlusions are common in PAD, front cutting enables engagement of tightest lesions.
<b>Concentric Lumens</b>		✓	✗			Concentric lumens facilitate straight line laminar flow.
<b>Differential Cutting</b>		✓	✗			Differential cutting targets only the plaque, minimizing the risk of vessel damage.
<b>Expandable Blade Technology</b>		✓				Expandable blades deliver more versatility, facilitating treatment from SFA to TPT.
<b>Lesion Type</b>	Total Occlusions	✓		✗	✗	Peripheral arterial disease rarely manifests as a single lesion type. A mix of disease morphologies is common, driving the need for a single device capable of addressing them all.
	Thrombus	✓			✗	
	Calcium	✓	✗	✗		
	Soft Plaque	✓		✗	✗	
	Fibrous Plaque	✓		✗	✗	



# Jetstream Components



# Jetstream XC Systems: eXpandable Cutter



XC 2.1/3.0 mm



XC 2.4/3.4 mm

XC 2.1/3.0 mm



- Ergonomic design for enhanced user controls
- Intuitive user interface facilitates single operator use
- Improved wire GARD\* simplifies wire management

- Two sizing options in a single device (eXpandable Cutter)
- Rotational/differential cutting tip removes all plaque types
- Active Aspiration ports collect plaque & thrombus
- 135 cm and 120 cm OTW lengths
- .014GW / 7F sheath compatible



XC 2.4/3.4 mm

\* Compared to previous generation





# Jetstream SC Systems: Single Cutter



SC 1.6 mm



SC 1.85 mm



- **Single Cutter** technology for tortuosity
- **Rotational/differential cutting tip** removes all plaque types
- **Aspiration ports** collect plaque & thrombus
- 145 cm OTW
- .014GW / 7F sheath compatible

SC 1.6 mm




SC 1.85 m

- *Ergonomic design for enhanced user experience*
- *Intuitive user interface facilitates single operator use*
- *Improved wire GARD\* simplifies wire management*

\* Compared to previous generation



# Jetstream: Selection Guide



# Preparation for Jetstream



- Introducers: 7F or larger
- Wires:
  - 0.014 inch high support wires, exchange length
  - no hydrophilic coated wires
  - Jetwire
- Filter:
  - in cases of high plaque burden
  - No single unit wire & filter



# Recommendations for Use



- When activating the Jetstream Catheter in a cutting mode advance only in a proximal to distal motion
- Complete two passes blades down followed by two passes blades up
- Advancement speed should be no faster than 1mm per second or using an engage – disengage technique listening to the motor RPMs
- REX back following each forward pass, providing active aspiration
- Always keep the tip of the Jetstream Catheter back 10cm from the guidewire spring tip



# Tips for Minimizing Distal Embolization

- Treat the lesion with BD except distal cap or just proximal to the most severe distal segment.
- Repeat the initial treatment with BU.
- Treat the distal cap or most severe distal segment of the vessel with BD followed by BU.
- Distal cap or severe distal lesion acts like a filter.
- *Protection against distal embolization is particularly important in CTO, mixed thrombotic-fibrotic plaques, calcified disease, long disease, and TASC D lesions*





# Jetstream-Ca<sup>++</sup>



## Intravascular ultrasound evaluation of JETSTREAM atherectomy removal of superficial calcium in peripheral arteries

Akiko Maehara<sup>1,2</sup>, MD; Gary S. Mintz<sup>3</sup>, MD; Thomas M. Shimshak<sup>1</sup>, MD; Joseph J. Ricotta 2nd<sup>4</sup>, MD, MS; Venkatesh Ramani<sup>5</sup>, MD; Malcolm T. Foster 3rd<sup>6</sup>, MD; Thomas P. Davis<sup>7</sup>, MD; William A. Gray<sup>1,8</sup>, MD

1. Columbia University Medical Center, New York, NY, USA; 2. Cardiovascular Research Foundation, New York, NY, USA; 3. Boston Franciscan Healthcare, Milwaukee, WI, USA; 4. Emory University, Atlanta, GA, USA; 5. Arizona Heart Institute, Phoenix, AZ, USA; 6. Temova Turkey Creek Medical Center, Knoxville, TN, USA; 7. St. John Hospital and Medical Center, Detroit, MI, USA

### KEYWORDS


- atherectomy
- calcium
- intravascular ultrasound (IVUS)
- peripheral arteries

### Abstract

**Aims:** Endovascular treatment of calcified femoral-popliteal disease is challenging. We sought to evaluate the mechanism of lumen gain when using the JETSTREAM Atherectomy System to treat calcified peripheral artery lesions.

**Methods and results:** The JETSTREAM Calcium Study was a prospective, single-arm, multicenter study to evaluate the JETSTREAM Atherectomy System for severely calcified femoral-popliteal artery lesions, i.e., patients with calcification and lesions with superficial calcium >90° and >5 mm in length as determined by intravascular ultrasound (IVUS). The 2.3 mm catheter was used in this study without distal protection. Fifty-five patients underwent angiographic screening; 26 (45%) met IVUS inclusion criteria. Angiographic calcium was moderate in eight cases and severe in 14, with no available data for four cases. Visual diameter stenosis was 86±9% pre-treatment, 37±13% post atherectomy, and 10±6% post adjunctive treatment (adjunctive PTA+stenting in eight and adjunct PTA alone in 16). IVUS showed lumen area increased from 6.6±3.7 mm<sup>2</sup> to 10.0±4.1, 6 mm<sup>2</sup> (p=0.091); calcium reduction was responsible for 86±23% of the lumen increase. Although the superficial calcium arc did not change (151±70° to 146±71°, p=0.83), the arc of reverberation increased (23±20° to 65±40°, p=0.006), indicating device-related modification of calcium. Adjunctive balloon angioplasty was performed in 62% of the lesions, and stent implantation in 31%. In 11 cases with adjunctive balloon dilation, the MLA increased from 7.1 (6.4, 7.8) mm<sup>2</sup> post atherectomy to 11.9 (10.3, 13.5) mm<sup>2</sup> post balloon (p<0.001) without flow-limiting dissection. No major adverse events occurred up to 30 days post procedure in either the study group or the patients who were excluded from the analysis.

**Conclusions:** The JETSTREAM Atherectomy System increased lumen dimensions in moderately or severely calcified femoral-popliteal lesions by removing superficial calcium without major complications.



	Pre-treatment	Post-atherectomy	p-value
Lumen area (mm <sup>2</sup> )	6.4 [5.5, 7.4]	9.6 [8.6, 10.6]	<0.0001
Minimum lumen diameter (mm)	2.2 [2.1, 2.4]	3.0 [2.8, 3.1]	<0.0001
Lumen symmetry index	0.68 [0.64, 0.72]	0.75 [0.71, 0.79]	<0.0001
Maximum superficial calcium (°)	146 [122, 169]	137 [110, 164]	0.12
Decrease of calcium area (mm <sup>2</sup> )	NA	2.2 [1.8, 2.7]	NA
Calcium reduction (%)	NA	77 [69, 86]	NA
<b>Surface shape of calcium</b>			
Convex	66% (46)	26% (18)	0.0005
Concave	34% (24)	74% (52)	
<b>Irregularity of superficial calcium</b>			
Irregular	54% (38)	31% (22)	0.02
Smooth	46% (32)	69% (48)	
Reverberation	34% (24)	43% (30)	0.14
Maximum arc of reverberation (°)	25 [15, 35]	70 [46, 95]	0.001
Values are least square means with 95% confidence interval or % (n).			



# Jetstream-ISR



J Endovasc Ther. 2016 Apr;23(2):339-46. doi: 10.1177/1526602816634028. Epub 2016 Feb 26.

## JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.

Shammas NW<sup>1</sup>, Shammas GA<sup>2</sup>, Banerjee S<sup>3</sup>, Popma JJ<sup>4</sup>, Mohammad A<sup>3</sup>, Jerin M<sup>5</sup>.

### ⊕ Author information

### Abstract

**PURPOSE:** To evaluate the outcomes and stent-device interaction of the JetStream atherectomy device in the treatment of in-stent restenosis (ISR) of the femoropopliteal segment.

**METHODS:** The JetStream XC atherectomy device, a rotational cutter with aspiration capacity, was evaluated in a prospective cohort of 29 patients (mean age  $69.9 \pm 11.7$  years; 11 men) with femoropopliteal ISR in 32 limbs (ClinicalTrials.gov identifier [NCT01722877](#)). Lesion length was  $17.4 \pm 13.1$  cm. The primary effectiveness outcome was acute success ( $\leq 30\%$  residual narrowing with no serious adverse events). The primary safety endpoint was major adverse events. Secondary endpoints included clinically driven target lesion revascularization (TLR) at 6 months and 1 year and loss of stent integrity as assessed by an angiographic core laboratory.

**RESULTS:** Treated length was  $19.5 \pm 12.9$  cm. Acute success was obtained in 29/32 (91%) limbs. Acute device success ( $<50\%$  residual narrowing after atherectomy alone) was 76% (22/29). Adjunctive balloon angioplasty was performed in all cases at a mean pressure of  $11.6 \pm 3.3$  atm. Embolic filter protection was used in 16 (50%) of 32 limbs. Macrodebris was noted in 2 (12%) of 16 filters. Distal embolization requiring treatment occurred in 3/32 (9.4%) limbs (2 with no filter). Other non-procedure-related adverse events were 1 (3%) death (nonvascular) and 1 (3%) case of major bleeding. There were no new stent fractures or deformities ( $n=24$ ) postatherectomy. Follow-up was completed on 27 patients (29 limbs) at 6 and 12 months. TLR at these time points occurred in 4/29 (14%) and 12/29 (41%) patients. Patency (duplex-derived peak systolic velocity ratio  $<2.4$ ) was 72% at 6 months.

**CONCLUSION:** JetStream atherectomy using the XC device has favorable acute results in treating femoropopliteal ISR with high procedure success, no device-stent interaction, and favorably low TLR rates. A multicenter trial is needed to confirm these results.

Acute device (alone) success 76%  
Filter use in 50%  
Distal embolization 9%




# M/61, (Rutherford 3) LHK, 3460319

Jetstream™ XC Atherectomy Catheter



○ 2.4 mm ☆ 3.4 mm






**M/61,** LHK, 3460319




IN.PACT 5 x 150, 6 x 60 mm




# IVUS




**Before athrectomy**



**After athrectomy**




**After DEB**








- CC: severe claudication in both legs (100 M) Rutherford 3
- PHx:
  - HTN
  - DM
  - CAD (3VD)
  - CKD (Cr 1.36, eGFR 51 ml/min)
  - S/P nephrectomy, due to RCC
  - S/P Prostate cancer




# Guidewire Crossing





# Atherectomy & DCB



Jetstream XC 2.4/3.4



InPACT DCB 6 x 120 & 5 x 150






# IVUS





**Before athrectomy**

**After athrectomy**

**After DCB**




# Post ABI






M/69, (AJS, #9749779)


- CC: Claudication (Rutherford 3)
- PHx:
  - HTN
  - Fem-to-fem bypass (2004) d/t Rt iliac a. occlusion
- Ex-smoker
- Echo: EF=68%
- Cr 0.84 mg/dL



# Bidirectional Approach




# Jetstream



# Balloon Dilation in Tibial Arteries




# Supera Stent






# Post ABI



**ABI 0.51**



**ABI 0.72**



# Take Home Messages



- In complex lesions such as long lesions, calcified lesions, and ISR lesions, DCB alone has limitations to achieve optimal results.
- Jetstream is a rotational atherectomy device with capability to remove calcium and thrombus. It's effective and relatively easy to use.
- Combining Jetstream with DCB may lower risk of dissections and improve immediate and late outcomes. This needs to be proved in future clinical trials.



ENdovascular & COronary REvascularization in Seoul

# ENCORE SEOUL 2017

SEPTEMBER 20(WED) ~ 22(FRI), 2017 GRAND INTERCONTINENTAL SEOUL PARNAS, SEOUL, KOREA

Sep 20 - 22, 2017

**Thank you for your attention!**

**See you in Seoul!**



**ENCORE SEOUL**  
Endovascular & Coronary Revascularization in Seoul